Accuray (NASDAQ:ARAY) Releases Quarterly Earnings Results, Hits Expectations

Accuray (NASDAQ:ARAY) released its quarterly earnings data on Wednesday. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04), Zacks reports. Accuray had a negative net margin of 3.48% and a negative return on equity of 33.65%. The business had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. During the same quarter in the previous year, the business earned ($0.03) EPS. Accuray updated its FY 2025 guidance to EPS.

Accuray Price Performance

Shares of ARAY stock traded up $0.06 during trading hours on Thursday, reaching $2.09. 1,645,853 shares of the company were exchanged, compared to its average volume of 483,350. Accuray has a fifty-two week low of $1.40 and a fifty-two week high of $3.05. The stock’s fifty day moving average is $1.89 and its two-hundred day moving average is $1.84. The company has a market cap of $209.56 million, a price-to-earnings ratio of -13.06 and a beta of 1.40. The company has a debt-to-equity ratio of 3.65, a current ratio of 1.66 and a quick ratio of 0.95.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.